# US 6,726,919 B2 · Injectable dispersion of propofol

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,726,919 B2
- Document ID: US6726919B2
- Status: Granted
- Kind: B2
- Application number: 09/880,104
- Filed: 2001-06-14
- Published: 2002-02-21
- Granted: 2004-04-27
- Earliest claimed: 2000-06-16
- Assignees: RTP Pharma Inc.
- Inventors: Gary W. Pace; Michael G. Vachon; Awadesh K. Mishra; Robert A. Snow
- Web page: https://patentgrep.com/patent/US6726919B2

## CPC

- A61K 31/7016: Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K31/7032)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/14: Quaternary ammonium compounds, e.g. edrophonium, choline (betaines A61K31/205)
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 23/00: Anaesthetics
- A61P 25/06: Antimigraine agents
- A61P 25/20: Hypnotics; Sedatives
- A61P 31/04: Antibacterial agents
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A sterile, injectable homogenized dispersion of micromatrices or microdroplets having a mean diameter from about 50 nm to about 1000 nm comprising about 1% to about 7.5% of propofol, about 1% to about 8% of a propofol-soluble diluent, and about 0.67% to about 5% of a surface stabilizing amphiphilic agent suspended in an aqueous medium containing a synergetic quantity of antimicrobial agent and a tonicity modifying amount of a pharmaceutically acceptable water-soluble hydroxyl-group-containing excipient, wherein the ratio of propofol to diluent is in the range of about 0.25 to about 7.5 while the ratio of propofol to amphiphilic agent is in the range from about 0.4 to about 1.5, and wherein the viscosity of the dispersion is in the range of 1.1 to 8 cps, processes for the formation of the dispersion, and methods of use are disclosed.

## Claims

### Claim 1

A sterile, injectable dispersion of micromatrices or microdroplets having a mean diameter from about 50 nm to about 1000 nm comprising:
propofol in an amount of from about 1% to about 7.5% by weight/volume of the dispersion,
a propofol-soluble diluent in an amount of from about 1% to about 8% by weight/volume of the dispersion, and
a surface stabilizing amphiphilic agent in an amount of from about 0.67% to about 5% by weight/volume of the dispersion, suspended in an aqueous medium containing
a synergetic quantity of antimicrobial agent and
a tonicity modifying amount of a pharmaceutically acceptable water-soluble hydroxyl-group-containing excipient,
wherein the ratio of propofol to diluent is in the range of about 0.25 to about 7.5, and the ratio of propofol to amphiphilic agent is in the range from about 0.4 to about 1.5.

### Claim 2 (depends on 1)

The dispersion of claim 1, wherein the diluent is selected from the group consisting of a C-2 to C-24 saturated fatty acid C-2 to C-24 alcohol ester, a C-8 to C-24 unsaturated fatty acid C-2 to C-24 alcohol ester, saturated and unsaturated naturally available and pharmaceutically acceptable hydrocarbons and hydrocarbon alcohols having from 15 to 35 carbon atoms, triglycerides of medium chain C-8 to C-12 saturated and unsaturated pharmaceutically acceptable fatty acids, triglycerides of long chain C-14 to C-30 saturated and unsaturated pharmaceutically acceptable fatty acids, a pharmaceutically acceptable oil from a vegetable or fish, and mixtures thereof.

### Claim 3 (depends on 2)

The dispersion of claim 2, wherein the oil is selected from the group consisting of soybean oil, safflower oil, cottonseed oil, corn oil, sunflower oil, arachis oil, castor oil, olive oil, and coconut oil, omega-3 polyunsaturated oils, omega-3 marine triglycerides, and combinations thereof.

### Claim 4 (depends on 1)

The dispersion of claim 1, wherein the diluent is selected from the group consisting of isopropyl myristate, isopropyl palmitate, cholesteryl oleate, ethyl oleate, palmitoyl acetate, squalene, squalane, MIGLYOL 810, capric-caprylic triglyceride, soybean oil, and mixtures thereof.

### Claim 5 (depends on 1)

The dispersion of claim 1, wherein the amphiphilic agent is selected from the group consisting of pharmaceutically acceptable phospholipids, pharmaceutically acceptable lecithins, and mixtures thereof.

### Claim 6 (depends on 1)

The dispersion of claim 1, wherein the amphiphilic agent is selected from the group consisting of egg lecithin, egg phosphatidylcholine, soy lecithin, soy phosphatidylcholine, 1,2-dimyristoyl-sn-glycero-3-phosphotidlycholine (DMPC), 1,2-dimyristoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (DMPG), L-alpha-phosphatidylcholine, palmitoyl-linoleoyl phosphatidylcholine, stearoyl-linoleoyl phosphatidylcholine, lysolecithin, phosphatidic acid, phosphatidyl-DL-glycerol, phosphatidylethanolamine, palmitoyl-oleoyl phosphatidylcholine, phosphatidylinositol, phosphatidylserine, 1,3-bis(sn-3-phosphatidyl)-sn-glycerol, 1,3-di(3-sn-phosphatidyl)-sn-glycerol, and mixtures thereof.

### Claim 7 (depends on 1)

The dispersion of claim 1, wherein the amphiphilic agent comprises a surfactant selected from the group consisting of a pharmaceutically acceptable non-ionic surfactant, a pharmaceutically acceptable ionic surfactant, and mixtures thereof.

### Claim 8 (depends on 1)

The dispersion of claim 1, wherein the hydroxyl-group-containing excipient is selected from the group consisting of a monosaccharide, a disaccharide, a trisaccharide, sucrose, dextrose, trehalose, mannitol, lactose, glycerol, glycerin, sorbitol, and mixtures thereof.

### Claim 9 (depends on 1)

The dispersion of claim 1, wherein the antimicrobial agent is selected from the group consisting of benzoic acid, benzyl alcohol, chlorobutanol, chlorocresol, cresol, dehydroacetic acid, phenol, phenylethyl alcohol, potassium benzoate, potassium sorbate, sodium benzoate, sodium dehydroacetate, sodium propionate, sorbic acid, and thymol, and mixtures thereof.

### Claim 10 (depends on 1)

The dispersion of claim 1, wherein the antimicrobial agent is selected from the group consisting of benzalkonium chloride, benzethonium chloride, butyl paraben, cetylpyridinium chloride, ethylparaben, methylparaben, methylparaben sodium, propylparaben, and propylparaben sodium, and mixtures thereof.

### Claim 11 (depends on 1)

The dispersion of claim 1, wherein propofol is present in an amount of from about 2% to about 5%.

### Claim 12 (depends on 11)

The dispersion of claim 11, wherein propofol is present in an amount of about 2%.

### Claim 13 (depends on 1)

The dispersion of claim 1, wherein the hydroxyl-group-containing excipient is mannitol.

### Claim 14 (depends on 13)

The dispersion of claim 13, wherein mannitol is present in an amount of from about 5.5% to about 7.5%.

### Claim 15 (depends on 14)

The dispersion of claim 14, wherein mannitol is present in an amount of about 5.5%.

### Claim 16 (depends on 1)

The dispersion of claim 1, wherein the propofol-soluble diluent is a medium chain triglyceride.

### Claim 17 (depends on 16)

The dispersion of claim 16, wherein the medium chain triglyceride is a triglyceride of a C-8 to C-12 saturated or unsaturated pharmaceutically acceptable fatty acid.

### Claim 18 (depends on 17)

The dispersion of claim 17, wherein the medium chain triglyceride is capric-caprylic triglyceride.

### Claim 19 (depends on 18)

The dispersion of claim 18, wherein the medium chain triglyceride is MIGLYOL 810.

### Claim 20 (depends on 16)

The dispersion of claim 16, wherein the medium chain triglyceride is present in an amount of from about 1% to about 4%.

### Claim 21 (depends on 20)

The dispersion of claim 20, wherein the medium chain triglyceride is present in an amount of from about 2% to about 4%.

### Claim 22 (depends on 21)

The dispersion of claim 21, wherein the medium chain triglyceride is present in an amount of about 4%.

### Claim 23 (depends on 1)

The dispersion of claim 1, wherein the amphiphilic agent is egg lecithin.

### Claim 24 (depends on 23)

The dispersion of claim 23, wherein the egg lecithin is present in an amount of from about 1.5% to about 5%.

### Claim 25 (depends on 24)

The dispersion of claim 24, wherein the egg lecithin is present in an amount of from about 0.67% to about 2.5%.

### Claim 26 (depends on 25)

The dispersion of claim 25, wherein the egg lecithin is present in an amount of about 1.6%.

### Claim 27 (depends on 1)

The dispersion of claim 1, which includes anionic dimyristoylphosphatidyl glycerol.

### Claim 28 (depends on 27)

The dispersion of claim 27, wherein the anionic dimyristoylphosphatidyl glycerol is present in an amount of 0.05% to 0.25%.

### Claim 29 (depends on 28)

The dispersion of claim 28, wherein the anionic dimyristoylphosphatidyl glycerol is present in an amount of 0.1%.

### Claim 30 (depends on 1)

The dispersion of claim 1, which includes egg lecithin and anionic dimyristoylphosphatidyl glycerol.

### Claim 31 (depends on 30)

The dispersion of claim 30, wherein the egg lecithin is present in an amount of about 1.5% to about 5% and the anionic dimyristoylphosphatidyl glycerol is present in an amount of 0.05% to 0.25%.

### Claim 32 (depends on 31)

The dispersion of claim 31, wherein the egg lecithin is present in an amount of about 1.6% and the anionic dimyristoylphosphatidyl glycerol is present in an amount of 0.1%.

### Claim 33 (depends on 1)

The dispersion of claim 1, wherein the pH of the dispersion is from about 5 to about 9.

### Claim 34 (depends on 33)

The dispersion of claim 33, wherein the pH of the dispersion is from about 5 to about 8.

### Claim 35 (depends on 34)

The dispersion of claim 34, wherein the pH of the dispersion is from about 6 to about 8.

### Claim 36 (depends on 1)

The dispersion of claim 1, wherein the dispersion is sealed in a vial under nitrogen.

### Claim 37 (depends on 36)

The dispersion of claim 36, wherein the vial is sealed with a stopper.

### Claim 38 (depends on 1)

The dispersion of claim 1, wherein the synergetic quantity of antimicrobial agent is about 0.01% to 0.45% w/v of propofol.

### Claim 39 (depends on 1)

The dispersion of claim 1, wherein the antimicrobial agent is benzyl alcohol.

### Claim 40 (depends on 39)

The dispersion of claim 39, wherein the synergetic quantity of benzyl alcohol is about 0.01% to 0.45% w/v of propofol.

### Claim 41 (depends on 1)

The dispersion of claim 1, wherein the synergetic quantity of antimicrobial agent is about 0.001% to about 0.01% w/v of propofol.

### Claim 42 (depends on 1)

The dispersion of claim 1, wherein the antimicrobial agent is EDTA.

### Claim 43 (depends on 1)

The dispersion of claim 1, wherein the synergistic quantity of antimicrobial agent is an amount of antimicrobial agent that permits no more than a 0.5 log increase over at least 7 days from the level of an initial inoculum of each of Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Candida albicans, and Aspergillus niger added at approximately 1000 colony forming units per milliliter to a reference dispersion at a temperature in the range of 20-25° C.

### Claim 44 (depends on 1)

The dispersion of claim 1, wherein the viscosity of the dispersion is in the range from about 1.1 to 8 cps at ambient temperature.

### Claim 45 (depends on 1)

The dispersion of claim 1, wherein the viscosity of the dispersion is in the range from about 1.1 to 8 cps at a temperature range from 20-25° C.

### Claim 46

A sterile, injectable dispersion of micromatrices or microdroplets having a mean diameter from about 50 nm to about 1000 nm comprising:
propofol in an amount of from about 1% to about 7.5% by weight/volume of the dispersion,
a medium chain triglyceride of a C-8 to C-12 saturated or unsaturated pharmaceutically acceptable fatty acid in an amount of from about 1% to about 8% by weight/volume of the dispersion, and
a surface stabilizing amphiphilic agent in an amount of from about 0.67% to about 5% by weight/volume, suspended in an aqueous medium containing
a synergetic quantity of antimicrobial agent and
a tonicity modifying amount of a pharmaceutically acceptable water-soluble hydroxyl-group-containing excipient,
wherein the ratio of propofol to diluent is in the range of about 0.25 to about 7.5, and the ratio of propofol to amphiphilic agent is in the range of about 0.4 to about 1.5.

### Claim 47

A sterile, injectable dispersion of micromatrices or microdroplets having a mean diameter from about 50 nm to about 1000 nm comprising:
propofol in an amount of about 2% by weight/volume of the dispersion,
a medium chain triglyceride of a pharmaceutically acceptable fatty acid in an amount of about 4% by weight/volume of the dispersion,
egg lecithin in an amount of about 1.6% by weight/volume of the dispersion, and
anionic dimyristoylphosphatidyl glycerol in an amount of 0.1% by weight/volume of the dispersion, suspended in an aqueous medium containing
a synergetic quantity of antimicrobial agent and
a tonicity modifying amount of a pharmaceutically acceptable water-soluble hydroxyl-group-containing excipient,
wherein the ratio of propofol to diluent is in the range of about 0.25 to about 7.5, and the ratio of propofol to amphiphilic agent is in the range of about 0.4 to about 1.5.

### Claim 48

A sterile, injectable dispersion of micromatrices or microdroplets having a mean diameter from about 50 nm to about 1000 nm comprising:
propofol in an amount of about 1% by weight/weight of the dispersion,
egg lecithin in an amount of about 1% by weight/weight of the dispersion,
anionic dimyristoylphosphatidyl glycerol in an amount of about 0.25% by weight/weight of the dispersion, and
ethyl oleate in an amount of about 3.75%, suspended in an aqueous medium containing
a synergetic quantity of antimicrobial agent and
a tonicity modifying amount of a pharmaceutically acceptable water-soluble hydroxyl-group-containing excipient,
wherein the weight ratio of propofol to diluent is in the range of about 0.25 to about 7.5, and the weight ratio of propofol to amphiphilic agent is in the range of about 0.4 to about 1.5.
